Vanguard DA2PI-CPV Lyophilisat et solvant pour suspension injectable pour chiens

Authorised

- Canine distemper virus, strain N-CDV, Live
- Canine parvovirus, strain NL-35-D, Live
- Canine adenovirus 2, strain Manhattan, Live
- Canine parainfluenza virus, strain NL-CPI-5, Live

Product identification

Medicine name:
Vanguard DA2PI-CPV Lyophilisat et solvant pour suspension injectable pour chiens

Active substance:
Canine distemper virus, strain N-CDV, Live

Canine parvovirus, strain NL-35-D, Live

Canine adenovirus 2, strain Manhattan, Live

Canine parainfluenza virus, strain NL-CPI-5, Live

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Canine distemper virus, strain N-CDV, Live
3.00 log10 50% cell culture infectious dose / 1.00 millilitre(s)

Canine parvovirus, strain NL-35-D, Live
7.00 log10 50% cell culture infectious dose / 1.00 millilitre(s)

Canine adenovirus 2, strain Manhattan, Live
3.20 log10 50% cell culture infectious dose / 1.00 millilitre(s)

Canine parainfluenza virus, strain NL-CPI-5, Live
6.00 log10 50% cell culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:
Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AD04

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Luxembourg

Available in:
Luxembourg

Package description:
Vanguard DA2PI-CPV 1 dose Vial Lyophilisate and solvent for suspension for injection
Vanguard DA2PI-CPV 10 1 dose Vial Lyophilisate and solvent for suspension for injection
Vanguard DA2PI-CPV 100 1 dose Vial Lyophilisate and solvent for suspension for injection
Vanguard DA2PI-CPV 25 1 dose Vial Lyophilisate and solvent for suspension for injection

---

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis Belgium

Marketing authorisation date:
1/12/1993

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
Ministry Of Health And Social Security

Authorisation number:
V 087/93/11/0351

Date of authorisation status change:
10/10/2008

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.